MedTrace Logo

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma

NCT01503827 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2021-01-07

No results posted yet for this study

Summary

People with brain metastases from melanoma are offered different treatment options after local treatment of their brain metastases via surgery or stereotactic irradiation. Depending on the treating institution and the clinician involved a patient may or may not be offered whole brain radiotherapy (WBRT) after their brain metastases are excised or treated with stereotactic irradiation. This trial seeks to determine if WBRT reduces the spread of brain metastases and lengthens the time to recurrence. The trial also examines the effect of WBRT on quality of life and brain functions such as memory, speech and concentration. Participants will be randomised after local treatment of their brain metastases to either WBRT or observation. 220 people will be recruited from sites in Australia, Norway, the UK, the US and other international sites.

Conditions

Interventions

RADIATION

WBRT

A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation

Sponsors & Collaborators

  • Trans Tasman Radiation Oncology Group

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • Melanoma and Skin Cancer Trials Limited

    lead OTHER

Principal Investigators

  • Gerald Fogarty, BSc, MBBS · Mater Hospital, St Vincent's Hospital, Melanoma Institue Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2017-09-30
Completion
2022-06-30

Countries

  • Australia
  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01503827 on ClinicalTrials.gov